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TUMOR CONTAMINATION IN THE BIOPSY PATH OF
PRIMARY MALIGNANT BONE TUMORS 
Marcelo Parente Oliveira1, Pablo Moura de Andrade Lima2, Roberto José Vieira de Mello3 
ABSTRACT
Objective: To study factors possibly associated with tu-
mor contamination in the biopsy path of primary ma-
lignant bone tumors. Method: Thirty-five patients who 
underwent surgical treatment with diagnoses of osteosar-
coma, Ewing’s tumor and chondrosarcoma were studied 
retrospectively. The sample was analyzed to characterize 
the biopsy technique used, histological type of the tumor, 
neoadjuvant chemotherapy used, local recurrences and tu-
mor contamination in the biopsy path. Results: Among the 
35 patients studied, four cases of contamination occurred 
(11.43%): one from osteosarcoma, two from Ewing’s tu-
mor and one from chondrosarcoma. There was no asso-
ciation between the type of tumor and presence of tumor 
contamination in the biopsy path (p = 0.65). There was 
also no association between the presence of tumor con-
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tamination and the biopsy technique (p = 0.06). On the 
other hand, there were associations between the presence 
of tumor contamination and local recurrence (p = 0.01) and 
between tumor contamination and absence of neoadjuvant 
chemotherapy (p = 0.02). Conclusion: Tumor contamina-
tion in the biopsy path of primary malignant bone tumors 
was associated with local recurrence. On the other hand, 
the histological type of the tumor and the type of biopsy 
did not have an influence on tumor contamination. Neo-
adjuvant chemotherapy had a protective effect against this 
complication. Despite these findings, tumor contamination 
is a complication that should always be taken into consi-
deration, and removal of the biopsy path is recommended 
in tumor resection surgery. 
Keywords – Neoplasm Seeding; Biopsy; Sarcoma; Bone Neo-
plasms; Neoplasm Recurrence, Local; Musculoskeletal System
INTRODUCTION
Malignant tumors of the musculoskeletal system are 
relatively rare forms of neoplasia, representing only 
0.2% of all new cases of cancer(1). Approximately 80% 
of them originate from soft tissues, and the remainder 
originate in bone tissue. On the other hand, they repre-
sent a group of very important diseases, given the mor-
bidity and mortality that they cause and their particular 
incidence among young patients, which gives rise to gre-
at impairment to the lives of the individuals affected(2-5). 
Dealing with these tumors requires integration of 
clinical, laboratory, radiographic and histological cha-
racteristics in order to achieve a precise diagnosis and 
management leading to successful treatment. In this 
respect, biopsy can be highlighted as a fundamental 
step in dealing with tumors of the musculoskeletal sys-
tem, and it is indispensable for achieving a definitive 
diagnosis and for identifying the histological pattern 
of the tumor(4,6,7). Biopsies should provide sufficient 
representative tissue sample for a precise diagnosis, 
but without excessively manipulating the lesion, so 
as to avoid modifying the tumor’s relationship with 
the anatomical compartments and contaminating the 
neighboring tissues with tumor cells(7). 
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titution (whether at HC-UFPE or elsewhere), team 
performing the biopsy and whether neoadjuvant che-
motherapy was administered. The following patients 
were excluded: those whose biopsy path was not re-
moved during the operation to resect the tumor; those 
whose biopsy path had not been examined from an 
anatomopathological point of view to define whether 
tumor cell contamination was present or absent; and 
those whose records did not present complete data for 
the required analyses. 
At HC-UFPE, whenever possible, it is preferred to 
perform biopsies by means of the percutaneous tech-
nique, except in cases in which there is a risk of injury 
to prime structures, or in some cases of repetition of 
the biopsy because the previous examination was in-
conclusive. In addition, biopsies are performed by the 
same team that will perform the surgical treatment of 
the lesion. With regard to the biopsy path, it is routi-
nely removed at the time of tumor resection surgery. 
To study the path, after this has been collected from 
the surgical specimen, the normal histological tech-
nique is used: fixing in 10% formol, dehydration in a 
series of alcohols, diaphanization, impregnation and 
embedding in paraffin, sectioning using a microtome 
and staining with hematoxylin and eosin); followed 
by analysis under an optical microscope to identify 
the presence or absence of tumor cells in the sample, 
which defines the presence or absence of tumor con-
tamination, respectively. 
All the patients in this study were operated by the 
same surgeon, who was one of the authors of this stu-
dy (PMAL), and the anatomopathological evaluations 
were performed by the same pathologist, who was 
also one of the authors of this study (RJVM). Some 
of the patients evaluated came with biopsies already 
performed at another clinic, and this variable was not 
controlled for in this study. 
It was observed that a total of 46 patients un-
derwent surgical treatment with the abovementioned 
diagnoses during the study period. Of these, 11 were 
excluded because their data were incomplete, thereby 
impeding analysis. Thus the sample available for this 
study comprised 35 patients, of which 19 were fema-
le and 16 were male, with a mean age of 30.7 years 
(ranging from eight to 77 years). 
The sample was analyzed to characterize the biop-
sy technique used (open or percutaneous), histologi-
cal type of tumor (osteosarcoma, Ewing’s tumor or 
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Many surgeons with experience in treating mus-
culoskeletal tumors advocate removal of the biopsy 
path at the time of surgically resecting the tumor, 
taking the view that this path is potentially conta-
minated by tumor cells(5,6,8-18). However, no basis 
for this practice has been found in any scientific 
studies, and it is based more on personal experience 
than on the current literature. Even so, many issues 
are covered in a wide variety of studies, and un-
tested hypotheses have arisen. Among these, there 
is a hypothesis that attempts to obtain several tis-
sue samples in biopsies are associated with greater 
dissemination and consequently greater likelihood 
of contamination of the biopsy path(11). Another 
hypothesis that has been published is that biop-
sies performed using a percutaneous technique are 
associated with less contamination of the biopsy 
path because they involve less manipulation of 
the tumor tissue(8,11,19-21). It has also been observed 
that contamination of the biopsy path occurs more 
frequently in cases of soft-tissue sarcoma than in 
bone and cartilage lesions(17). It is also believed 
that implementing neoadjuvant chemotherapy has 
a protective effect with regard to controlling tumor 
infiltration at the biopsy site(20,22) and that this con-
tamination has a negative value in the prognosis for 
affected patients(23).
In the literature, there is a lack of detailed stu-
dies on biopsy paths in cases of musculoskeletal 
tumors(17,20,21). Knowledge of the characteristics of 
contamination of biopsy paths within orthopedic on-
cology may provide important support for improving 
biopsy techniques and for following up patients affec-
ted by these tumors. 
The aim of the present study was to study the 
factors possibly associated with tumor contamination 
of the biopsy path in cases of primary malignant 
bone tumors.
METHODS
A retrospective study was conducted on the medi-
cal files of all patients who underwent surgical tre-
atment with a diagnosis of osteosarcoma, Ewing’s 
tumor or chondrosarcoma at Hospital das Clínicas, 
Federal University of Pernambuco (HC-UFPE), be-
tween June 2005 and July 2011. The analysis was 
conducted independently of gender and age, biopsy 
technique used (whether open or percutaneous), ins-
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chondrosarcoma), neoadjuvant chemotherapy used 
(yes or no), local recurrence and tumor contamination 
of the biopsy path (present or absent) (Table 1). The 
data were catalogues in contingency tables and were 
subjected to statistical analysis. Hypotheses were 
analyzed by means of Fisher’s exact test and the G 
test with Williams correction. The descriptive level (p 
value) was taken to be 5%. The BioEstat 5.0 software 
was used for analyzing the data. 
Table 1 – Patient distribution according to diagnosis, biopsy technique, use of neoadjuvant chemotherapy, presence of local recurrence and occurrence 
of tumor contamination in the biopsy path.
Case Diagnosis Biopsy technique Neoadjuvant chemotherapy Local recurrence
Contamination of the 
biopsy path
1 Osteosarcoma Percutaneous Yes No No
2 Osteosarcoma Percutaneous Yes No No
3 Osteosarcoma Percutaneous Yes No No
4 Osteosarcoma Percutaneous Yes No No
5 Osteosarcoma Percutaneous Yes No No
6 Osteosarcoma Percutaneous Yes No No
7 Osteosarcoma Percutaneous Yes No No
8 Osteosarcoma Percutaneous Yes No Yes
9 Osteosarcoma Percutaneous Yes No No
10 Osteosarcoma Percutaneous Yes No No
11 Osteosarcoma Percutaneous Yes No No
12 Osteosarcoma Open Yes No No
13 Osteosarcoma Percutaneous No No No
14 Osteosarcoma Percutaneous Yes No No
15 Osteosarcoma Percutaneous Yes No No
16 Ewing’s tumor Percutaneous Yes No No
17 Ewing’s tumor Open Yes No No
18 Ewing’s tumor Percutaneous Yes No No
19 Ewing’s tumor Percutaneous Yes No No
20 Ewing’s tumor Open Yes No No
21 Ewing’s tumor Percutaneous Yes No No
22 Ewing’s tumor Open Yes No No
23 Ewing’s tumor Open No Yes Yes
24 Ewing’s tumor Open No Yes Yes
25 Ewing’s tumor Open Yes No No
26 Chondrosarcoma Percutaneous * No No
27 Chondrosarcoma Percutaneous * No No
28 Chondrosarcoma Open * No Yes
29 Chondrosarcoma Percutaneous * No No
30 Chondrosarcoma Open * No No
31 Chondrosarcoma Percutaneous * No No
32 Chondrosarcoma Open * No No
33 Chondrosarcoma Percutaneous * No No
34 Chondrosarcoma Percutaneous * No No
35 Chondrosarcoma Percutaneous * No No
* For the cases of chondrosarcoma, neoadjuvant chemotherapy did not apply.
RESULTS
Out of the 35 patients studied, 15 cases (42.86%) 
were osteosarcoma, 10 cases (28.57%) were Ewing’s 
tumor and 10 cases (28.57%) were chondrosarcoma. 
Contamination of the biopsy path was observed in 
four of the 35 patients evaluated, representing 11.43% 
of the sample. Among these, there was one case of 
osteosarcoma, two of Ewing’s tumor and one of chon-
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drosarcoma. No association between the tumor type 
and the presence of tumor contamination in the biopsy 
path was observed (p = 0.65). 
In analyzing the sample as a whole, it was obser-
ved that out of the four cases that presented conta-
mination, three were biopsied by means of the open 
technique and one by means of the percutaneous 
technique. There was no statistically significant di-
fference (p = 0.06) in relation to the cases without 
contamination, regarding the biopsy technique. The 
variable of chemotherapy could only be evaluated in 
relation to the cases of osteosarcoma and Ewing’s 
tumor, which are the types of tumor to which this 
therapeutic method applies. Thus, there were three 
contaminations in 25 cases. One of these three cases 
received neoadjuvant chemotherapy and two of them 
did not. Among the cases without contamination, 21 
received neoadjuvant chemotherapy and one did not. 
There was a statistically significant difference betwe-
en the groups (p = 0.02), thus showing an association 
between not administering neoadjuvant chemotherapy 
and occurrence of contamination in the biopsy path. 
Regarding local recurrence, it was observed that out 
of the four patients who presented contamination, two 
evolved with this complication. None of the cases 
without contamination presented local recurrence. In 
relation to this variable, a statistically significant di-
fference was observed between the groups with and 
without contamination (p = 0.01). 
In evaluating the data relating to each type of tumor 
individually, it was observed that in the cases of osteo-
sarcoma, contamination occurred in 15 of the patients 
studied (6.67%). In relation to the biopsy technique used, 
the case that presented contamination was biopsied using 
the percutaneous technique. In the cases without conta-
mination, one was biopsied using the open technique 
and 13 using the percutaneous technique. It was not 
possible to detect any association between the biopsy 
technique used and occurrences of contamination in the 
osteosarcoma cases (p = 0.93). It was also observed that 
the case with contamination in the biopsy path and 13 
out of the 14 cases without contamination received neo-
adjuvant chemotherapy, while one of the cases without 
contamination did not receive it. Again, no association 
was detected between this variable and occurrences of 
contamination in the biopsy path (p = 0.93). In relation 
to local recurrence, none of the patients with a diagnosis 
of osteosarcoma presented this complication. 
Regarding the cases of Ewing’s tumor, two ca-
ses of contamination occurred among the 10 patients 
studied (20%). These two cases occurred in patients 
who had not received neoadjuvant chemotherapy. On 
the other hand, the other eight patients who received 
neoadjuvant chemotherapy did not present contamina-
tion. It was observed that in these cases, not adminis-
tering neoadjuvant chemotherapy was associated with 
occurrences of contamination in the biopsy path (p = 
0.02). Regarding the biopsy technique used, no sta-
tistically significant difference was observed between 
the patients who underwent open biopsy and those 
with percutaneous biopsy in relation to occurrences of 
contamination of the path. There was contamination 
in two of the six cases of open biopsy and no con-
tamination in any of the four cases of percutaneous 
biopsy (p = 0.33). Regarding local recurrence, the two 
cases with contamination presented this complication, 
while the other eight cases without contamination did 
not; there was a statistically significant difference be-
tween the patients with and without contamination, in 
relation to local recurrence (p = 0.02). 
Among the patients with a diagnosis of chon-
drosarcoma, contamination occurred in 10 patients 
studied (10%). This contamination occurred in one 
patient who underwent open biopsy. In the nine cases 
without contamination, two received open biopsy and 
seven, percutaneous biopsy. No association was de-
tected between the biopsy technique and occurrences 
of contamination among the patients with a diagnosis 
of chondrosarcoma (p = 0.30). In relation to local 
recurrence, none of the patients with a diagnosis of 
chondrosarcoma presented this complication.
DISCUSSION 
The perception that the biopsy path in cases of 
musculoskeletal tumors might be contaminated by 
tumor cells seems to have been reinforced within the 
orthopedic community through the study by Cannon 
and Dyson(18), who reported that there was statistically 
significant lower occurrence of local tumor recurrence 
in cases in which the biopsy path was resected, in 
comparison with the cases in which it was not. The 
literature pertinent to this topic reveals that local re-
currence was constantly observed in a series of reports 
on cases in which the biopsy path had not been resec-
ted(19,22-27). On the other hand, in studies by Kaffen-
berger et al(21) and Saghieh et al(28), in which biopsy 
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paths produced using the percutaneous technique had 
not been resected, no local recurrence was observed. 
In our sample, it was seen that among the four 
cases that presented contamination, there was local 
recurrence in two cases, thus showing a statistically 
significant difference in relation to local recurrence in 
the group without contamination (p = 0.01). When the 
sample was individualized according to the histologi-
cal type of the tumor, it was observed that there was 
no local recurrence among the cases of osteosarcoma 
and chondrosarcoma. On the other hand, among the 
cases of Ewing’s tumor, it was observed that the two 
cases that presented contamination evolved with local 
recurrence, while none of the eight cases without con-
tamination presented this complication, and this was a 
statistically significant difference between the groups 
(p = 0.02). Taking into consideration both the results 
found in the present study sample and the analyses 
in the literature, the possibility for local recurrence 
in patients whose biopsy path had not been removed 
was considerable. Thus the practice of resecting the 
path is recommendable despite what was shown in the 
studies by Kaffenberger et al(21) and Saghieh et al(28).
Some authors believe that because biopsies per-
formed using the percutaneous technique involve less 
manipulation of the tumor tissue, they are associated 
with lower occurrence of path contamination(8,11,13). 
In our sample, out of the four patients with contami-
nation, three underwent open biopsy and one, per-
cutaneous biopsy. However, despite this difference, 
no statistically significant difference was observed 
in relation to patients without contamination, with 
regard to the biopsy technique used (p = 0.06). When 
the sample was individualized according to the type 
of tumor, again there was no association between the 
biopsy technique and occurrences of contamination in 
the cases of osteosarcoma (p = 0.93), Ewing’s tumor 
(p = 0.33) or chondrosarcoma (p = 0.30). 
In analyzing a set of eight cases of tumor conta-
mination in biopsy paths made in the musculoskele-
tal system that were reported in the literature(19,22-26), 
it was observed that percutaneous biopsy was per-
formed in seven of them(19,22-25) and open biopsy in 
one case(26). Also analyzing the literature, Mohana 
et al(20) observed two cases of contamination among 
six cases of open biopsy (33.3%) and three cases of 
contamination among 20 cases of percutaneous biop-
sy (15%). No reference was made to the criteria for 
choosing the biopsy technique, and it was not sta-
ted whether there was homogeneity between the two 
groups. Although the authors believed that biopsies 
using the percutaneous technique presented lower risk 
of contamination of their path, compared with the 
open technique, no statistical method was used to test 
this hypothesis. In the study by Ribeiro et al(17) four 
cases of contamination occurred among seven open 
biopsies (57.1%) while there were another four cases 
of contamination among 18 percutaneous biopsies 
(22.2%). These authors also did not perform statistical 
tests to evaluate the significance of these differences. 
It should be noted that they studies both bone tumors 
and soft-tissue tumors, and that all the bone tumors 
underwent percutaneous biopsy, while all the soft-
-tissue tumors underwent open biopsy by means of 
mini-incisions. Thus, in comparing the occurrences 
of contamination between the open and percutaneous 
techniques in their study, it needs to be borne in mind 
that the biopsy technique chosen was different for the 
different tumor types, thus making the two groups 
very heterogenous. In the studies by Kaffenberger 
et al(21) and Saghieh et al(28), all the biopsies were 
performed by means of the percutaneous technique. 
In these two studies, no contamination of the biop-
sy path occurred. Although the results shown in the 
present study sample and the observations made in 
the literature indicate a tendency for biopsies using 
the percutaneous technique to be associated with less 
local recurrence than with open biopsy, this cannot be 
considered statistically. The main remark that should 
be put forward is that tumor contamination in biopsy 
paths is a reality even in biopsies performed using 
percutaneous techniques, thus reinforcing the need for 
path removal at the time of tumor resection. 
Another issue raised in the literature is the influen-
ce of the type of tumor on occurrences of tumor conta-
mination in the biopsy path(17,29). Ribeiro et al(17), who 
studied both bone and soft-tissue tumors, found four 
cases of contamination (57.1%) among seven cases 
of soft-tissue tumors and four cases of contamina-
tion (22.2%) among 18 cases of bone tumors. These 
authors suggested that greater cellularity and lower 
quantities of matrix, which are particular characteris-
tics of soft-tissue sarcomas, would be related to greater 
cell dissemination, in comparison with bone tumors. 
However, they stressed that no statistical test was per-
formed to assess the significance of this difference. 
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Among the 35 patients in our study, there were four 
cases of contamination: one out of the 15 osteosar-
coma cases, two out of the 10 Ewing’s tumor cases 
and one out of the 10 chondrosarcoma cases. No as-
sociation between the type of tumor and occurrences 
of contamination (p = 0.64). 
Some authors believe that neoadjuvant chemothe-
rapy has a protective effect with regard to controlling 
tumor infiltration at the biopsy site(20,22). Mohana et 
al(20) observed that the occurrence rate of tumor con-
tamination among patients who received neoadjuvant 
chemotherapy was 12.5% (three out of 24 cases). In 
their sample, the only two cases that did not receive 
neoadjuvant chemotherapy evolved with contamina-
tion in the biopsy path. However, it should be no-
ted that the three patients who received neoadjuvant 
chemotherapy and presented contamination had poor 
responses to chemotherapy. In the study by Saghieh 
et al(28), in which neoadjuvant chemotherapy was ad-
ministered to all the patients, there was no contami-
nation in the biopsy path. In our sample, the effect of 
neoadjuvant chemotherapy could only be evaluated 
for the cases of osteosarcoma and Ewing’s tumor, sin-
ce these are the tumor types to which this therapeu-
tic method applies. Thus, there were three cases of 
contamination out of 25 cases studied (12%). Among 
these three cases, two did not receive neoadjuvant che-
motherapy while one did. Among the cases without 
contamination, 21 received neoadjuvant chemotherapy 
and one did not, and thus there was an association 
between occurrence of contamination and not admi-
nistering neoadjuvant chemotherapy (p = 0.02). When 
the osteosarcoma cases were analyzed separately, this 
statistically significant difference was not observed
(p = 0.93), thus differing from the cases of Ewing’s 
tumor (p = 0.02). It should be noted that we did not 
evaluate the tumor response to the chemotherapeutic 
regimen used, although this is a factor that could be 
taken into consideration in evaluating the effect of neo-
adjuvant chemotherapy as a protection against tumor 
contamination. Analysis on our sample and observa-
tions on the results from the studies by Mohana et al(20) 
and Saghieh et al(28) reinforce the idea that this thera-
peutic method has some protective influence against 
occurrences of tumor contamination in the biopsy path. 
The limitations of our study include the small sam-
ple size, which may have compromised the analysis 
on the phenomena studied. However, in studies that 
deal with tumors of the musculoskeletal system, this 
is a frequently occurring reality, because of the rela-
tive rarity of these tumors. In addition to this issue, 
the diversity of the diagnoses studied and the hetero-
geneity of the cases may be limiting factors regarding 
the observations made. Moreover, there was a lack 
of well defined criteria for choosing the biopsy tech-
nique to be used, and there was no control over the 
clinic where the biopsy had been performed. Another 
matter that deserves to be taken into consideration is 
that the staging of the tumors was also not controlled 
for in this study, and the tumors were also not divi-
ded into their subtypes, which are known to present 
differentiated behavior. 
CONCLUSION 
The presence of tumor contamination in the bi-
opsy path of primary malignant bone tumors was 
associated with local recurrence. On the other hand, 
it was not shown to be influenced by the type of 
biopsy performed or the type of tumor studied. Neo-
adjuvant chemotherapy was shown to be an effective 
protector against this event. Despite these findings, 
tumor contamination is a complication that should 
always be taken into consideration, and removal of 
the biopsy path is recommended in cases of tumor 
resection surgery.
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